“Since the discovery of the JAK2 mutation in 2005, there has been tremendous excitement about the development of selective JAK2 inhibitors as a new treatment for MPNs. After six years of waiting, several drugs are in advanced clinical trials and one may soon be available for patients. Given these new drugs and other lines of clinical investigation, there are many reasons to be optimistic about the prospects for a cure.” - John Crispino, PhD, Northwestern Memorial Hospital, Scientific Advisor for MPN Research Foundation

Available Treatments

 

Become a member

Free membership includes MPN Update newsletter, alerts, RFP announcements and more.

Join today

 

 

 

Your donation goes a long way.

Learn more about how you can help support the MPN Research Foundation and the impact your contributions can make.

Donate Now
 
 
 

Connect with Us

MPN Research Foundation wants to hear from you. Connect with us through our social networks or send us an email.

Email Facebook Twitter LinkedIn